Legal & General Group
HOWL icon

Legal & General Group’s Werewolf Therapeutics HOWL Stock Holding History

Legal & General Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,642
Closed -$2.57K – 3468
2025
Q1 		$2.57K Hold
2,642
– – ﹤0.01% 3339
2024
Q4 		$3.91K Hold
2,642
– – ﹤0.01% 3359
2024
Q3 		$5.6K Hold
2,642
– – ﹤0.01% 3359
2024
Q2 		$6.39K Buy
+2,642
New +$12.7K ﹤0.01% 3359
2022
Q2 		– Sell
-2,613
Closed -$11K – 3584
2022
Q1 		$11K Buy
2,613
+121
+5% +$848 ﹤0.01% 3383
2021
Q4 		$30K Buy
2,492
+1,756
+239% +$26.5K ﹤0.01% 3149
2021
Q3 		$13K Hold
736
– – ﹤0.01% 3400
2021
Q2 		$13K Buy
+736
New +$10.1K ﹤0.01% 3399

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Legal & General Group's HOWL Position: Q2 2025 in Review

Legal & General Group sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 2,642 shares — an estimated $2.57K sold.

Legal & General Group first reported a position in HOWL in Q2 2021 and held it in 8 quarters. The position peaked at $30K in Q4 2021. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Legal & General Group reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,642 Werewolf Therapeutics shares in Q2 2025, an estimated $2.57K.
  • Legal & General Group first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's Werewolf Therapeutics position peaked at $30K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.